Launching new medicines - a major bottleneck in the pharma industry

Updated: May 19

Sequential launching medicines coupled with reference pricing is costing pharma companies hundreds of million dollars in forgone revenue.

OGT is proposing a simultaneous launch of new medicines in all considered markets with Optimal Global Launch Pricing.


This is a two part proposition:

- Pricing function - to keep regulatory agencies appraised of potential launch prices throughout the 12 years R&D process, with documents:

- INDP - Investigation New Drug Prices

- NDAP - New Drug Application Prices

- Actual launch optimal pricing


Next few blogs will detail and come up with live examples.

Recent Posts

See All

Flexcell Office Park

Suite 500

2730 Tucker St.

Burlington, NC 27215

Call

T: 919-451-3675

  • facebook
  • Twitter Clean
  • w-googleplus